Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for <i>FLT3</i>- mutated acute myeloid leukemia patients – Czech center experience

• Barbora Weinbergerová,
• Martin Čerňan,
• Tomáš Kabut,
• Lukáš Semerád,
• Natália Podstavková,
• Tomáš Szotkowski,
• Ivana Ježíšková,
• Jiří Mayer

Affiliations

Barbora Weinbergerová

Department of Internal Medicine – Hematology and Oncology, Masaryk University, Brno, Czech Republic; Department of Internal Medicine – Hematology and Oncology, University Hospital Brno, Brno, Czech Republic

Martin Čerňan

Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic

Tomáš Kabut

Department of Internal Medicine – Hematology and Oncology, Masaryk University, Brno, Czech Republic; Department of Internal Medicine – Hematology and Oncology, University Hospital Brno, Brno, Czech Republic

Lukáš Semerád

Department of Internal Medicine – Hematology and Oncology, Masaryk University, Brno, Czech Republic; Department of Internal Medicine – Hematology and Oncology, University Hospital Brno, Brno, Czech Republic

Natália Podstavková

Department of Internal Medicine – Hematology and Oncology, Masaryk University, Brno, Czech Republic; Department of Internal Medicine – Hematology and Oncology, University Hospital Brno, Brno, Czech Republic

Tomáš Szotkowski

Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic

Ivana Ježíšková

Department of Internal Medicine – Hematology and Oncology, Masaryk University, Brno, Czech Republic; Department of Internal Medicine – Hematology and Oncology, University Hospital Brno, Brno, Czech Republic

Jiří Mayer

Department of Internal Medicine – Hematology and Oncology, Masaryk University, Brno, Czech Republic; Department of Internal Medicine – Hematology and Oncology, University Hospital Brno, Brno, Czech Republic